PE20241129A1 - Inhibidores de parp1 de azetidina y pirrolidina y usos de estos - Google Patents
Inhibidores de parp1 de azetidina y pirrolidina y usos de estosInfo
- Publication number
- PE20241129A1 PE20241129A1 PE2024000584A PE2024000584A PE20241129A1 PE 20241129 A1 PE20241129 A1 PE 20241129A1 PE 2024000584 A PE2024000584 A PE 2024000584A PE 2024000584 A PE2024000584 A PE 2024000584A PE 20241129 A1 PE20241129 A1 PE 20241129A1
- Authority
- PE
- Peru
- Prior art keywords
- deuterium
- halogen
- azetidine
- pyrrolidine
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163251469P | 2021-10-01 | 2021-10-01 | |
| US202263339597P | 2022-05-09 | 2022-05-09 | |
| US202263402835P | 2022-08-31 | 2022-08-31 | |
| PCT/US2022/045415 WO2023056039A1 (en) | 2021-10-01 | 2022-09-30 | Azetidine and pyrrolidine parp1 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20241129A1 true PE20241129A1 (es) | 2024-05-24 |
Family
ID=85783565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000584A PE20241129A1 (es) | 2021-10-01 | 2022-09-30 | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20230159525A1 (https=) |
| EP (1) | EP4408420A4 (https=) |
| JP (2) | JP7592220B2 (https=) |
| KR (2) | KR102867210B1 (https=) |
| CN (2) | CN120058698A (https=) |
| AU (2) | AU2022356286B2 (https=) |
| CA (1) | CA3232775A1 (https=) |
| CL (2) | CL2024000877A1 (https=) |
| CO (1) | CO2024003949A2 (https=) |
| CR (1) | CR20240144A (https=) |
| DO (1) | DOP2024000060A (https=) |
| IL (2) | IL311376B2 (https=) |
| MX (2) | MX2024003922A (https=) |
| PE (1) | PE20241129A1 (https=) |
| TW (2) | TWI876212B (https=) |
| WO (1) | WO2023056039A1 (https=) |
| ZA (1) | ZA202404648B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102867210B1 (ko) | 2021-10-01 | 2025-10-14 | 신테라, 인크. | 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도 |
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| AU2023259236B2 (en) | 2022-04-28 | 2025-01-09 | Xinthera, Inc. | Tricyclic parp1 inhibitors and uses thereof |
| CN119487027A (zh) * | 2022-04-28 | 2025-02-18 | 宁波新湾科技发展有限公司 | 作为parp1抑制剂的化合物 |
| EP4534537A4 (en) * | 2022-05-25 | 2025-12-10 | Xizang Haisco Pharmaceutical Co Ltd | BICYCLE-DERIVED PARP INHIBITOR AND ITS USE |
| CN118119629A (zh) * | 2022-09-30 | 2024-05-31 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
| WO2024099416A1 (zh) * | 2022-11-10 | 2024-05-16 | 上海海和药物研究开发股份有限公司 | 一种稠合三环类parp1抑制剂、其制备方法及用途 |
| KR20250103668A (ko) * | 2022-11-10 | 2025-07-07 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 축합 이환 화합물 |
| WO2024206172A1 (en) * | 2023-03-24 | 2024-10-03 | Xinthera, Inc. | Crystalline forms of an azetidine parp1 inhibitor |
| TW202506680A (zh) * | 2023-04-28 | 2025-02-16 | 美商思諾維新醫藥公司 | 作為ｐａｒｐ１抑制劑之雜環化合物 |
| CN121358725A (zh) | 2023-06-14 | 2026-01-16 | 海思科医药集团股份有限公司 | 双环衍生物parp抑制剂及其用途 |
| TW202535877A (zh) * | 2023-11-01 | 2025-09-16 | 大陸商正大天晴藥業集團股份有限公司 | 含有稠合雙環的化合物、藥物組合物及其用途 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| US8404713B2 (en) | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| BRPI0820701A2 (pt) * | 2007-12-11 | 2015-06-16 | Cytopathfinder Inc | Composto de carboxamida e seu uso como agonistas do receptor de quimiocina |
| CN102341394B (zh) | 2009-01-23 | 2015-04-15 | 武田药品工业株式会社 | 聚(adp-核糖)聚合酶(parp)抑制剂 |
| EP2459561A1 (en) | 2009-07-30 | 2012-06-06 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| PL2912032T3 (pl) | 2012-10-26 | 2020-11-16 | Nerviano Medical Sciences S.R.L. | Pochodne 4-karboksyamido-izoindolinonu jako selektywne inhibitory parp-1 |
| CA2941716A1 (en) | 2014-03-07 | 2015-09-11 | The Johns Hopkins University | Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs) |
| CN105753814A (zh) | 2015-01-01 | 2016-07-13 | 成都贝斯凯瑞生物科技有限公司 | 取代氮杂环衍生物及其应用 |
| MX375707B (es) | 2015-06-09 | 2025-03-06 | Onconic Therapeutics Inc | Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo. |
| CR20180168A (es) * | 2015-08-17 | 2018-06-27 | Lupin Ltd | Derivados de heteroarilo como inhibidores de parp |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| IL283127B1 (en) | 2018-11-14 | 2026-02-01 | Smilebiotek Zhuhai Ltd | Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders |
| SI3999506T1 (sl) | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
| US12459899B2 (en) * | 2019-10-30 | 2025-11-04 | DIGMBIO, Inc. | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| US11591331B2 (en) | 2021-04-19 | 2023-02-28 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
| EP4328224A4 (en) | 2021-04-22 | 2025-06-18 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | PARP INHIBITOR WITH PIPERAZINE STRUCTURE, MANUFACTURING METHOD THEREOF AND PHARMACEUTICAL USE THEREOF |
| WO2022222966A1 (zh) | 2021-04-23 | 2022-10-27 | 成都百裕制药股份有限公司 | 一种选择性parp1抑制剂及其应用 |
| CN115702156A (zh) | 2021-04-23 | 2023-02-14 | 南京明德新药研发有限公司 | 吡啶酰胺类化合物 |
| WO2022222965A1 (zh) | 2021-04-23 | 2022-10-27 | 成都百裕制药股份有限公司 | 吡啶衍生物及其在医药上的应用 |
| AU2022261029A1 (en) | 2021-04-23 | 2023-10-19 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Heterocyclic derivative inhibitor and preparation method therefor and application thereof |
| WO2022228387A1 (en) * | 2021-04-26 | 2022-11-03 | Fochon Biosciences, Ltd. | Compounds as parp inhibitors |
| BR112023022496A2 (pt) | 2021-05-24 | 2024-01-16 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos |
| CN115403595A (zh) | 2021-05-27 | 2022-11-29 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| BR112023024942A2 (pt) | 2021-06-16 | 2024-02-15 | Repare Therapeutics Inc | Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer |
| AU2022334408A1 (en) | 2021-08-27 | 2024-02-15 | Impact Therapeutics (Shanghai), Inc. | Substituted tricyclic compounds as parp inhibitors and use thereof |
| CN118119618A (zh) | 2021-09-09 | 2024-05-31 | 南京奥利墨斯医药科技有限公司 | 一种杂芳环类化合物及其应用 |
| WO2023046034A1 (zh) | 2021-09-22 | 2023-03-30 | 明慧医药（杭州）有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| WO2023046158A1 (zh) | 2021-09-26 | 2023-03-30 | 张文燕 | 氮杂喹啉酮类化合物及其医药用途 |
| WO2023046149A1 (zh) | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
| EP4410792A4 (en) | 2021-09-30 | 2025-12-03 | Xizang Haisco Pharmaceutical Co Ltd | NITROGEN-CONTAINS HETEROCYCLIC DERIVATIVE FOR USE AS A PARP INHIBITOR AND ITS USE |
| WO2023051716A1 (zh) | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 杂芳基衍生物parp抑制剂及其用途 |
| EP4410791A4 (en) | 2021-09-30 | 2025-10-22 | Xizang Haisco Pharmaceutical Co Ltd | BICYCLIC DERIVATIVE PARP INHIBITOR AND ITS USE |
| KR102867210B1 (ko) | 2021-10-01 | 2025-10-14 | 신테라, 인크. | 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도 |
| WO2023061406A1 (zh) | 2021-10-12 | 2023-04-20 | 微境生物医药科技(上海)有限公司 | 含三并环结构的parp抑制剂、及其制备方法和医药用途 |
| US20250289800A1 (en) | 2021-11-19 | 2025-09-18 | Kangbaida (Sichuan) Biotechnology Co., Ltd. | Selective Parp1 Inhibitor And Application Thereof |
| CN116143776A (zh) | 2021-11-22 | 2023-05-23 | 南京圣和药业股份有限公司 | Parp1抑制剂及其应用 |
| KR20240144125A (ko) | 2021-12-17 | 2024-10-02 | 키테라 (쑤저우) 바이오-파마슈티컬스 컴퍼니 리미티드 | Parp 억제제, 이를 포함하는 약제학적 조성물, 및 이의 용도 |
| WO2023133413A1 (en) | 2022-01-07 | 2023-07-13 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| CN118434725B (zh) | 2022-01-20 | 2026-01-02 | 微境生物医药科技(上海)有限公司 | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 |
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| CN116535401A (zh) | 2022-01-25 | 2023-08-04 | 南京圣和药业股份有限公司 | 新的parp1抑制剂及其应用 |
| WO2023143236A1 (zh) | 2022-01-26 | 2023-08-03 | 中国药科大学 | 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用 |
| JP7794989B2 (ja) | 2022-01-27 | 2026-01-06 | シンセラ， インコーポレイテッド | Ｐａｒｐ１阻害薬及びその使用 |
| WO2023147009A1 (en) | 2022-01-27 | 2023-08-03 | The Johns Hopkins University | Clinical-grade therapeutic progenitors generated from tankyrase/parp-inhibited pluripotent stem cell banks |
| WO2023146960A1 (en) | 2022-01-28 | 2023-08-03 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| KR20230116457A (ko) | 2022-01-28 | 2023-08-04 | 경북대학교 산학협력단 | 작약 추출물을 포함하는 만성폐쇄성폐질환 예방 또는 치료용 약학적 조성물 |
| EP4469046A1 (en) | 2022-01-28 | 2024-12-04 | Oulun Yliopisto | Compounds for use in the treatment of cancer and inflammatory conditions |
| IL314895A (en) | 2022-02-16 | 2024-10-01 | Duke Street Bio Ltd | Pharmaceutical compound |
| CN115232129B (zh) | 2022-08-18 | 2023-12-01 | 上海闻耐医药科技有限公司 | 一种parp1选择性抑制剂及其制备方法和用途 |
-
2022
- 2022-09-30 KR KR1020247013788A patent/KR102867210B1/ko active Active
- 2022-09-30 IL IL311376A patent/IL311376B2/en unknown
- 2022-09-30 CN CN202510199687.4A patent/CN120058698A/zh active Pending
- 2022-09-30 CR CR20240144A patent/CR20240144A/es unknown
- 2022-09-30 JP JP2024518681A patent/JP7592220B2/ja active Active
- 2022-09-30 CN CN202280064954.1A patent/CN118019532B/zh active Active
- 2022-09-30 TW TW111137289A patent/TWI876212B/zh active
- 2022-09-30 MX MX2024003922A patent/MX2024003922A/es unknown
- 2022-09-30 KR KR1020257032459A patent/KR20250145706A/ko active Pending
- 2022-09-30 AU AU2022356286A patent/AU2022356286B2/en active Active
- 2022-09-30 CA CA3232775A patent/CA3232775A1/en active Pending
- 2022-09-30 PE PE2024000584A patent/PE20241129A1/es unknown
- 2022-09-30 IL IL318196A patent/IL318196A/en unknown
- 2022-09-30 US US17/957,584 patent/US20230159525A1/en not_active Abandoned
- 2022-09-30 EP EP22877395.8A patent/EP4408420A4/en active Pending
- 2022-09-30 TW TW114104894A patent/TW202542152A/zh unknown
- 2022-09-30 WO PCT/US2022/045415 patent/WO2023056039A1/en not_active Ceased
-
2023
- 2023-02-28 US US18/115,314 patent/US11802128B2/en active Active
-
2024
- 2024-03-26 CL CL2024000877A patent/CL2024000877A1/es unknown
- 2024-03-26 DO DO2024000060A patent/DOP2024000060A/es unknown
- 2024-03-27 CO CONC2024/0003949A patent/CO2024003949A2/es unknown
- 2024-03-27 MX MX2024012801A patent/MX2024012801A/es unknown
- 2024-06-14 ZA ZA2024/04648A patent/ZA202404648B/en unknown
- 2024-11-19 JP JP2024201685A patent/JP2025024130A/ja active Pending
-
2025
- 2025-01-09 AU AU2025200139A patent/AU2025200139A1/en active Pending
- 2025-03-06 CL CL2025000629A patent/CL2025000629A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20241129A1 (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| PE20230238A1 (es) | Inhibidores de kras g12c | |
| MX2025009239A (es) | Compuestos triciclicos para el tratamiento de cancer | |
| PY2240956A (es) | Nuevos Compuestos bicíclicos y sus usos | |
| PE20200700A1 (es) | Compuestos macrociclicos y usos de los mismos | |
| MX2021014096A (es) | Compuestos heterociclicos, metodos de preparacion y usos de estos. | |
| PE20250021A1 (es) | Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8 | |
| AR035812A1 (es) | Compuestos de acrilamida farmaceuticamente efectivos como inhibidores de la enoil-acp reductasa-fabi-; composiciones formuladas con dichos compuestos, metodo para inhibir dicha reductasa , respectivamente, para tratar infecciones bacterianas utilizando dichos compuestos y uso de los compuestos menci | |
| AR119018A1 (es) | Inhibidores de proteína quinasas dependientes de adn | |
| PE20212329A1 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cancer | |
| PE20181491A1 (es) | Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| UY28578A1 (es) | Derivados de amida | |
| PE20231311A1 (es) | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos | |
| AR049898A1 (es) | Compuestos aminocarbonil fenilo sustituidos, composicion farmaceutica,uso y proceso para prepararlos | |
| AR034270A1 (es) | 1-aril- o 1-alquilsulfonil-heterociclilbenzazoles como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento | |
| PE20240652A1 (es) | Compuestos que inhiben la isoforma alfa de pi3k y metodos para tratar el cancer | |
| AR111315A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR062409A1 (es) | Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto | |
| PE20230680A1 (es) | Inhibidores de il4i1 y metodos de uso | |
| CL2023002549A1 (es) | Ciertos compuestos de pladienolida y métodos de uso (divisional). | |
| MX2024013019A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| PE20252243A1 (es) | Inhibidores de kif 18a y usos de los mismos | |
| AR045155A1 (es) | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos |